| abstract |
The present disclosure provides methods of treating malignancies comprising administering an effective dose of chimeric receptor (eg, CAR or TCR) gene-modified T cell immunotherapy. Some aspects of the present disclosure relate to methods of characterizing the pre-infusion tumor microenvironment and determining effective doses of T cell immunotherapy. |